Keytruda’s new approval was based on findings from the Phase III KEYNOTE-868 study, in which Keytruda plus carboplatin and paclitaxel, followed by Keytruda alone, reduced the risk of disease progression or death by 40% in patients whose cancer was mismatch repair proficient (pMMR) and by 70% those with dMMR tumours, compared to placebo with carboplatin and paclitaxel followed by placebo alone.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.